4 citations
,
January 2022 in “Dermatologic Therapy” Spironolactone is useful for treating acne and other skin conditions like excessive hair growth and certain types of hair loss.
219 citations
,
October 2009 in “Steroids” 5α-reductase inhibitors, like Finasteride and Dutasteride, help manage benign prostatic hyperplasia.
April 2018 in “The Journal of Urology” Dutasteride use can lead to a stable decline in sexual function that is not affected by age or prostate size.
Spironolactone effectively treats hormonal acne, hair loss, and excess hair growth in women.
15 citations
,
September 2005 in “The Journal of the American Animal Hospital Association/Journal of the American Animal Hospital Association” Trilostane effectively treated hair loss in Alaskan Malamutes with no adverse effects.
21 citations
,
October 2015 in “Current Drug Targets” Both dutasteride and finasteride improve urinary symptoms, but dutasteride may be better at reducing the risk of prostate surgery and sudden inability to urinate.
October 2023 in “Journal of the American Academy of Dermatology” Clascoterone cream could be used for other skin conditions affected by hormones.
September 2015 in “American journal of biomedicine”
7 citations
,
November 2014 in “Clinical Therapeutics” Finasteride and tamsulosin hydrochloride can be safely taken together without significant interaction.
2 citations
,
April 2024 in “Urology Annals” Taking dutasteride every other day works as well as daily and better preserves sexual function.
November 2024 in “Nanomaterials” The nanocrystalline suspension effectively delivers dutasteride over time with minimal inflammation.
5 citations
,
February 2014 in “Journal of Liquid Chromatography & Related Technologies” Method accurately measures finasteride and tamsulosin in combined drug form.
1 citations
,
September 2016 in “Acta Chromatographica” Created method to measure doxazosin mesylate and finasteride together.
Trilostane generally improved symptoms in dogs with Cushing's syndrome, but dosage adjustments were needed over time.
26 citations
,
September 2018 in “Neurobiology of Disease” Finasteride and dutasteride reduce unwanted movements from Parkinson's disease treatment by normalizing certain brain signals.
November 2023 in “Circulation” Minoxidil can cause a rare but serious condition that leads to fluid buildup around the heart and drug-induced lupus.
1 citations
,
August 2022 in “Journal of Dermatological Treatment” Dutasteride is the most effective for hair loss but may cause sexual and mental side effects.
October 2025 in “Advanced Healthcare Materials” Stevioside-based microneedles improve minoxidil delivery and hair growth for treating hair loss.
April 1992 in “Current opinion in therapeutic patents” New steroids were patented as effective for treating acne, hair loss, and other conditions related to hormones.
7 citations
,
August 2010 in “Medicinal Chemistry Research” Some synthesized compounds were more effective than Finasteride in reducing prostate cancer cell growth and androgen levels.
Spironolactone is effective and safe for treating acne.
20 citations
,
August 2019 in “Expert Opinion on Drug Safety” Some medications for bladder problems can cause memory issues or mood changes, and doctors should monitor these side effects.
April 2025 in “European Journal of Pharmaceutics and Biopharmaceutics” The new drug delivery system improves bicalutamide skin retention for better treatment of hair loss.
September 2024 in “Journal of Cutaneous and Aesthetic Surgery” Bicalutamide may help treat female pattern hair loss.
1 citations
,
September 2024 in “African Journal of Urology” Dutasteride is slightly better than finasteride for treating BPH but has fewer sexual side effects.
42 citations
,
May 2003 in “Mini-reviews in Medicinal Chemistry” New steroidal compounds could be effective for treating conditions related to 5α-reductase enzyme activity.
April 2025 in “International Journal of Pharmaceutics” Liposomes improve minoxidil delivery to hair follicles, enhancing treatment for hair loss.
19 citations
,
October 2019 in “Clinical and Experimental Dermatology” Spironolactone, an androgen antagonist, was reported to significantly reduce pain, lesion count, and Hidradenitis Suppurativa Physician Global Assessment (HSPGA) scores in patients with hidradenitis suppurativa (HS). Despite the lack of robust evidence for antiandrogens in HS treatment, studies by Golbari et al. and Lee and Fischer demonstrated positive outcomes in patients treated with spironolactone, including a significant reduction in HSPGA and lesion count in a cohort and in 20 patients, respectively.
19 citations
,
January 1993 in “Dermatologic Clinics” 97 citations
,
May 2004 in “British Journal of Urology” Dual therapy with specific medications can help manage male urinary symptoms and reduce side effects.